Company / Cost of Revenue
Haemonetics Cost of Revenue History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$611.9M
FY2024
5-year range
$487.7M / $617.5M
FY2020-FY2024
Trend
-0.9%
vs FY2023
Sector context
#57 of 107
Health Care
What the data says
At $612M, Haemonetics's cost of revenue ranks #51 of 107 in the Health Care sector. Cost of Revenue has fluctuated over the past 9 years, ranging from $473M in FY2020 to $618M in FY2023.
Based on SEC 10-K filings.
$612M in FY2024 with a 5-year CAGR of +4.0%.
Increased from $554M to $612M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +7.9%
- 5-Year CAGR
- +4.0%
- 10-Year CAGR
- -
Sector benchmark
#51 of 107 in Health CareTop 47% of 107This company $611.9M Sector average $11.8B
▼
-94.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.0%, indicating consistent growth.
- In FY2024, cost of revenue decreased 0.9% year-over-year.
- Ranks #57 out of 107 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $611.9M | -0.9% |
| FY2023 | $617.5M | +11.6% |
| FY2022 | $553.6M | +13.5% |
| FY2021 | $487.7M | +3.2% |
| FY2020 | $472.6M | -6.2% |
| FY2019 | $504.0M | -8.4% |
| FY2018 | $550.0M | +11.8% |
| FY2017 | $492.0M | -3.1% |
| FY2016 | $507.6M | +0.9% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026